NCT02451488View on ClinicalTrials.gov

Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma

PHASE4CompletedINTERVENTIONAL

Enrollment

8

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

November 4, 2016

Study Completion Date

November 4, 2016

Conditions

Melanoma

Interventions

DRUG

GM-CSF

14 days in a dose of 125 µg/m\^2

OTHER

Standard of Care

No neo-adjuvant therapy prior to surgical intervention

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER